Insider trade

Director sold ~$130K of DXCM shares in the open market

Traded Sep 14, 2026 · Filed Sep 16, 2026

DexcomDXCM

~$130K
Reported value · 1,550 sh @ $84.02: 36K
Holds after · shares reported: +1.8%
stock since the trade · S&P 500 +0.4%, $84.68 → $86.23 on Oct 1

Why it stands out

A board member of Dexcom sold $130K of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 14, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 16, 2026

DirectorIndirect holding$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$130,231

Shares × reported transaction price

Timing vs results

46 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $84.68 on Sep 14, 2026, 54% above its 52-week low and 8% below its high, after a 1% rise over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $92.34 (Aug 21, 2026), 80% of the way up, from 251 adjusted closes. 30 trading days earlier: $83.45 on Jul 31, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

3 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-0.5%	+0.6%	-1.1%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-26-000179
Filed / recorded: Sep 16, 2026, 8:26 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Nicholas Augustinos
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 14, 2026
Transaction code: S
Shares / units: 1,550
Price per share: $84.02
Acquired / disposed: Disposed (D)
Shares owned after: 35,832
Ownership form: Indirect — by Trust
Amendment: No

Footnotes from the filing

On June 10, 2026, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The shares set forth above were sold pursuant to the 10b5-1 Plan.
Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee.

Around the same time

Officer sold ~$221K of Dexcom

Scheduled in advance5d ago

Officer plans to sell ~$221K of Dexcom

Planned, from pay7d ago

Director sold ~$550K of Dexcom

Scheduled in advance3w ago